New hope for rare brain disease: YA-101 enters Mid-Stage trial
Disease control
Recruiting now
This study tests a new drug, YA-101, in 75 people with multiple system atrophy (MSA), a rare brain disease that affects movement and body functions. The goal is to see if the drug is safe and can help control the disease. Participants will receive either YA-101 or a placebo, and …
Phase: PHASE2 • Sponsor: Dasher Neuroscience Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC